page_banner2

Licensing & Business Development

There are hundreds of Chinese pharmaceutical and medical technology companies with the capability and resources to secure significant distribution for your product. The challenge is finding the right partner.

The right partner is a company that has an effective mix of attributes to get a deal done and make your product a success.

Corporate

– Strategic commitment to the therapy area or target sector
– Executive team prepared to execute prequalified deals
– Sufficient understanding of deal type and structure
– History of successfully financed projects

Technical

– Internal expertise for any local clinical study requirements
– In-house regulatory team for most likely State Food and Drug Administration (SFDA) approval
– Strong relationships with the SFDA to secure product approval

Market
– Sales and marketing resources
– More importantly, sales and marketing understanding
– Direct access to the right distribution channels
– Necessary government relationships for reimbursement and tenders

Our experience and in-depth knowledge of China’s market helps you to secure the right partner, quickly.

Working with TPP Healthcare: Our team acts as your China business development department. We interface with Chinese firms, arranging confidentiality agreements, exchanging diligence documentation, and negotiating term sheets. We’re there to guide you through the challenges and adventures of doing business in China.

We work on an exclusive representation basis: a simple agreement that prevents circumvention and rewards us based on successful deals. This can take the form of fixed fees or a percentage of sales revenue, depending on the deal structure with Chinese partners. In certain circumstances, for particular types of product, TPP will license the product itself and arrange distribution directly.

Connect with us to discuss licensing & business development projects in China.

p

Contributed toward Ironwood’s search for its strategic partnership in China with novel IBS/constipation drug Linzess. Ironwood announced a partnership deal with AstraZeneca in China, in which AstraZeneca paid $25m upfront for the partnership.
Assisted Stallergenes with the development of a market entry strategy for two products. Helped the company to develop a specific partnership structure including JV, MA to build its presence in China.

Sample Deals

Assisted Ipsen in seeking a strategic partnership in China with a late stage asset. Also helped to expand Ipsen’s partnership with key opinion leaders in leading academic institutes in China for early stage collaboration.
Contributed to The Medicines Company’s securement of a licensing deal for ANGIOMAX® (bivalirudin) and CLEVIPREX® (clevidipine) with SciClone Pharmaceuticals for total upfront and milestones of >$50m.

p

Supported Icon’s strategic expansion in China through M&A and partnership. Assisted Icon in being acquired by Beijing Wits in 2012.
Helped the Australian biotech company to divest an HIV/HBV compound in preclinical development. The process involved more than four parties to close the deal.